Alemtuzumab Improves Contrast Sensitivity in Relapsing-Remitting Multiple Sclerosis Patients

Update Item Information
Identifier 20110208_nanos_posters_002
Title Alemtuzumab Improves Contrast Sensitivity in Relapsing-Remitting Multiple Sclerosis Patients
Creator Laura Balcer; Steven Galetta; Maureen Maguire; Jeffrey Palmer; David Margolin; Marco Rizzo
Affiliation (SG) (MM) University of Pennsylvania, Philadelphia, PA; (JP) (DM) (MR) Genzyme Corporation, Cambridge, MA
Subject Contrast Sensitivity; Pelli-Robson, Multiple Sclerosis (MS); Vision; Alemtuzumab
Description Alemtuzumab is a humanized monoclonal antibody that alters the circulating lymphocyte pool. In a 3-year, phase 2 trial, alemtuzumab was superior to subcutaneous IFNB-1a in patients with early, active relapsing-remitting MS (RRMS), significantly reducing relapse rate, risk for sustained accumulation of disability, and mean disability.
Date 2011-02-08
Language eng
Format application/pdf
Type Text
Source 2011 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2011: Poster Presentations
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2011. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s66t3t4h
Setname ehsl_novel_nam
ID 181645
Reference URL https://collections.lib.utah.edu/ark:/87278/s66t3t4h
Back to Search Results